Because elevated levels of PD-L1 in breast cancer patients correlates with increased survival (Fig. 3b, c) and increased likelihood of response to a PD-L1 immune checkpoint blockade,47 we hypothesized that the combination of an immune checkpoint inhibitor and LG268 would further increase the infiltration of cytotoxic CD8 T cells. Here, CD8A is linked to breast carcinoma.